nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolterodine—CHRM4—Monoamine GPCRs—DRD4—conduct disorder	0.0314	0.0338	CbGpPWpGaD
Tolterodine—CHRM5—Monoamine GPCRs—DRD4—conduct disorder	0.0301	0.0323	CbGpPWpGaD
Tolterodine—Chlorphenamine—SLC6A4—conduct disorder	0.0279	0.402	CrCbGaD
Tolterodine—CHRM4—Amine ligand-binding receptors—DRD4—conduct disorder	0.0264	0.0284	CbGpPWpGaD
Tolterodine—CHRM5—Amine ligand-binding receptors—DRD4—conduct disorder	0.0253	0.0272	CbGpPWpGaD
Tolterodine—Atomoxetine—SLC6A4—conduct disorder	0.0235	0.338	CrCbGaD
Tolterodine—CHRM1—Monoamine GPCRs—DRD4—conduct disorder	0.0212	0.0228	CbGpPWpGaD
Tolterodine—CHRM3—Monoamine GPCRs—DRD4—conduct disorder	0.0211	0.0227	CbGpPWpGaD
Tolterodine—CHRM2—Monoamine GPCRs—DRD4—conduct disorder	0.0209	0.0225	CbGpPWpGaD
Tolterodine—CHRM4—Monoamine GPCRs—HTR2A—conduct disorder	0.0205	0.022	CbGpPWpGaD
Tolterodine—CHRM5—Monoamine GPCRs—HTR2A—conduct disorder	0.0196	0.0211	CbGpPWpGaD
Tolterodine—Atomoxetine—HTR2A—conduct disorder	0.018	0.26	CrCbGaD
Tolterodine—CHRM1—Amine ligand-binding receptors—DRD4—conduct disorder	0.0178	0.0191	CbGpPWpGaD
Tolterodine—CHRM3—Amine ligand-binding receptors—DRD4—conduct disorder	0.0178	0.0191	CbGpPWpGaD
Tolterodine—CHRM2—Amine ligand-binding receptors—DRD4—conduct disorder	0.0176	0.0189	CbGpPWpGaD
Tolterodine—CHRM4—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0172	0.0185	CbGpPWpGaD
Tolterodine—CHRM5—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0165	0.0177	CbGpPWpGaD
Tolterodine—CHRM1—Monoamine GPCRs—HTR2A—conduct disorder	0.0138	0.0149	CbGpPWpGaD
Tolterodine—CHRM3—Monoamine GPCRs—HTR2A—conduct disorder	0.0138	0.0148	CbGpPWpGaD
Tolterodine—CHRM2—Monoamine GPCRs—HTR2A—conduct disorder	0.0136	0.0147	CbGpPWpGaD
Tolterodine—CHRM4—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.0135	0.0145	CbGpPWpGaD
Tolterodine—CHRM5—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.0129	0.0139	CbGpPWpGaD
Tolterodine—CYP2C19—Melatonin metabolism and effects—MAOA—conduct disorder	0.0122	0.0131	CbGpPWpGaD
Tolterodine—KCNH2—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.0121	0.013	CbGpPWpGaD
Tolterodine—KCNH2—Neuronal System—GABRA2—conduct disorder	0.0119	0.0128	CbGpPWpGaD
Tolterodine—CHRM1—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0116	0.0125	CbGpPWpGaD
Tolterodine—CHRM3—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0116	0.0124	CbGpPWpGaD
Tolterodine—CHRM2—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0115	0.0123	CbGpPWpGaD
Tolterodine—CYP2D6—Melatonin metabolism and effects—MAOA—conduct disorder	0.0112	0.012	CbGpPWpGaD
Tolterodine—CYP3A4—Estrogen metabolism—COMT—conduct disorder	0.0108	0.0116	CbGpPWpGaD
Tolterodine—CHRM3—GPCRs, Other—DRD4—conduct disorder	0.00938	0.0101	CbGpPWpGaD
Tolterodine—CHRM2—GPCRs, Other—DRD4—conduct disorder	0.00929	0.00998	CbGpPWpGaD
Tolterodine—CHRM4—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00928	0.00997	CbGpPWpGaD
Tolterodine—KCNH2—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.00908	0.00976	CbGpPWpGaD
Tolterodine—CHRM1—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.00908	0.00976	CbGpPWpGaD
Tolterodine—CHRM3—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.00905	0.00973	CbGpPWpGaD
Tolterodine—CHRM2—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.00896	0.00963	CbGpPWpGaD
Tolterodine—CHRM5—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00888	0.00955	CbGpPWpGaD
Tolterodine—KCNH2—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.0074	0.00795	CbGpPWpGaD
Tolterodine—CHRM4—GPCR ligand binding—CGA—conduct disorder	0.00706	0.00759	CbGpPWpGaD
Tolterodine—CHRM5—GPCR ligand binding—CGA—conduct disorder	0.00677	0.00727	CbGpPWpGaD
Tolterodine—CHRM4—G alpha (i) signalling events—DRD4—conduct disorder	0.00653	0.00702	CbGpPWpGaD
Tolterodine—CHRM2—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.00642	0.0069	CbGpPWpGaD
Tolterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00626	0.00672	CbGpPWpGaD
Tolterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00624	0.0067	CbGpPWpGaD
Tolterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00618	0.00664	CbGpPWpGaD
Tolterodine—CHRM3—GPCRs, Other—HTR2A—conduct disorder	0.00612	0.00658	CbGpPWpGaD
Tolterodine—CHRM4—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00606	0.00652	CbGpPWpGaD
Tolterodine—CHRM2—GPCRs, Other—HTR2A—conduct disorder	0.00606	0.00651	CbGpPWpGaD
Tolterodine—CHRM5—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00581	0.00624	CbGpPWpGaD
Tolterodine—KCNH2—Neuronal System—COMT—conduct disorder	0.00574	0.00617	CbGpPWpGaD
Tolterodine—KCNH2—Neuronal System—MAOA—conduct disorder	0.0057	0.00613	CbGpPWpGaD
Tolterodine—CYP2C19—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00552	0.00593	CbGpPWpGaD
Tolterodine—CHRM1—Circadian rythm related genes—SLC6A4—conduct disorder	0.00531	0.00571	CbGpPWpGaD
Tolterodine—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.0052	0.00558	CbGpPWpGaD
Tolterodine—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00508	0.00546	CbGpPWpGaD
Tolterodine—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00504	0.00541	CbGpPWpGaD
Tolterodine—CHRM1—Circadian rythm related genes—DRD4—conduct disorder	0.00499	0.00537	CbGpPWpGaD
Tolterodine—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00498	0.00535	CbGpPWpGaD
Tolterodine—CHRM5—G alpha (q) signalling events—HTR2A—conduct disorder	0.0049	0.00527	CbGpPWpGaD
Tolterodine—CHRM2—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.00483	0.00519	CbGpPWpGaD
Tolterodine—CHRM1—GPCR ligand binding—CGA—conduct disorder	0.00476	0.00512	CbGpPWpGaD
Tolterodine—CHRM3—GPCR ligand binding—CGA—conduct disorder	0.00475	0.0051	CbGpPWpGaD
Tolterodine—CHRM2—GPCR ligand binding—CGA—conduct disorder	0.0047	0.00505	CbGpPWpGaD
Tolterodine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00438	0.00471	CbGpPWpGaD
Tolterodine—CHRM2—G alpha (i) signalling events—DRD4—conduct disorder	0.00435	0.00467	CbGpPWpGaD
Tolterodine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00409	0.00439	CbGpPWpGaD
Tolterodine—CHRM3—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00408	0.00438	CbGpPWpGaD
Tolterodine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00404	0.00434	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—CGA—conduct disorder	0.00399	0.00429	CbGpPWpGaD
Tolterodine—CHRM4—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00396	0.00425	CbGpPWpGaD
Tolterodine—CHRM4—GPCR ligand binding—DRD4—conduct disorder	0.00396	0.00425	CbGpPWpGaD
Tolterodine—CHRM2—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.00394	0.00423	CbGpPWpGaD
Tolterodine—KCNH2—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00392	0.00421	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—CGA—conduct disorder	0.00382	0.00411	CbGpPWpGaD
Tolterodine—CHRM5—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00379	0.00407	CbGpPWpGaD
Tolterodine—CHRM5—GPCR ligand binding—DRD4—conduct disorder	0.00379	0.00407	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—CGA—conduct disorder	0.00363	0.0039	CbGpPWpGaD
Tolterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.0035	0.00376	CbGpPWpGaD
Tolterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00349	0.00375	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—CGA—conduct disorder	0.00347	0.00373	CbGpPWpGaD
Tolterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00346	0.00372	CbGpPWpGaD
Tolterodine—CHRM1—G alpha (q) signalling events—HTR2A—conduct disorder	0.00345	0.00371	CbGpPWpGaD
Tolterodine—CHRM3—G alpha (q) signalling events—HTR2A—conduct disorder	0.00344	0.0037	CbGpPWpGaD
Tolterodine—CHRM4—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00339	0.00364	CbGpPWpGaD
Tolterodine—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00332	0.00357	CbGpPWpGaD
Tolterodine—CHRM5—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00325	0.00349	CbGpPWpGaD
Tolterodine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00309	0.00332	CbGpPWpGaD
Tolterodine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00308	0.00331	CbGpPWpGaD
Tolterodine—CYP2C19—Biological oxidations—COMT—conduct disorder	0.00295	0.00317	CbGpPWpGaD
Tolterodine—CYP2C19—Biological oxidations—MAOA—conduct disorder	0.00293	0.00315	CbGpPWpGaD
Tolterodine—CYP2C19—Metapathway biotransformation—COMT—conduct disorder	0.00291	0.00313	CbGpPWpGaD
Tolterodine—CYP2D6—Biological oxidations—COMT—conduct disorder	0.00272	0.00292	CbGpPWpGaD
Tolterodine—CYP2D6—Biological oxidations—MAOA—conduct disorder	0.0027	0.0029	CbGpPWpGaD
Tolterodine—CYP2C9—Biological oxidations—COMT—conduct disorder	0.00269	0.00289	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—CGA—conduct disorder	0.00269	0.00289	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—CGA—conduct disorder	0.00268	0.00288	CbGpPWpGaD
Tolterodine—CYP2D6—Metapathway biotransformation—COMT—conduct disorder	0.00268	0.00288	CbGpPWpGaD
Tolterodine—CYP2C9—Biological oxidations—MAOA—conduct disorder	0.00267	0.00287	CbGpPWpGaD
Tolterodine—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00267	0.00287	CbGpPWpGaD
Tolterodine—CHRM1—GPCR ligand binding—DRD4—conduct disorder	0.00267	0.00287	CbGpPWpGaD
Tolterodine—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00266	0.00286	CbGpPWpGaD
Tolterodine—CHRM3—GPCR ligand binding—DRD4—conduct disorder	0.00266	0.00286	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—CGA—conduct disorder	0.00266	0.00286	CbGpPWpGaD
Tolterodine—CYP2C9—Metapathway biotransformation—COMT—conduct disorder	0.00266	0.00285	CbGpPWpGaD
Tolterodine—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00263	0.00283	CbGpPWpGaD
Tolterodine—CHRM2—GPCR ligand binding—DRD4—conduct disorder	0.00263	0.00283	CbGpPWpGaD
Tolterodine—CHRM4—GPCR ligand binding—HTR2A—conduct disorder	0.00258	0.00277	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00251	0.0027	CbGpPWpGaD
Tolterodine—CHRM5—GPCR ligand binding—HTR2A—conduct disorder	0.00247	0.00266	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—CGA—conduct disorder	0.00244	0.00263	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—CGA—conduct disorder	0.00244	0.00262	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—CGA—conduct disorder	0.00241	0.00259	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00229	0.00246	CbGpPWpGaD
Tolterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00229	0.00246	CbGpPWpGaD
Tolterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00228	0.00245	CbGpPWpGaD
Tolterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00226	0.00242	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—DRD4—conduct disorder	0.00224	0.0024	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CGA—conduct disorder	0.00214	0.0023	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—DRD4—conduct disorder	0.00214	0.0023	CbGpPWpGaD
Tolterodine—CHRM2—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00209	0.00224	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CGA—conduct disorder	0.00205	0.0022	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—DRD4—conduct disorder	0.00203	0.00218	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—DRD4—conduct disorder	0.00194	0.00209	CbGpPWpGaD
Tolterodine—CYP3A4—Biological oxidations—COMT—conduct disorder	0.00178	0.00191	CbGpPWpGaD
Tolterodine—CYP3A4—Biological oxidations—MAOA—conduct disorder	0.00176	0.0019	CbGpPWpGaD
Tolterodine—CYP3A4—Metapathway biotransformation—COMT—conduct disorder	0.00175	0.00188	CbGpPWpGaD
Tolterodine—CHRM1—GPCR ligand binding—HTR2A—conduct disorder	0.00174	0.00187	CbGpPWpGaD
Tolterodine—CHRM3—GPCR ligand binding—HTR2A—conduct disorder	0.00174	0.00186	CbGpPWpGaD
Tolterodine—CHRM1—Circadian rythm related genes—EP300—conduct disorder	0.00173	0.00185	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—CGA—conduct disorder	0.00172	0.00185	CbGpPWpGaD
Tolterodine—CHRM2—GPCR ligand binding—HTR2A—conduct disorder	0.00172	0.00185	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—WASF1—conduct disorder	0.00172	0.00184	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—WASF1—conduct disorder	0.00164	0.00177	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—DRD4—conduct disorder	0.00151	0.00162	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—DRD4—conduct disorder	0.0015	0.00161	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—DRD4—conduct disorder	0.00149	0.0016	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—HTR2A—conduct disorder	0.00146	0.00157	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CGA—conduct disorder	0.00144	0.00155	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CGA—conduct disorder	0.00144	0.00155	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CGA—conduct disorder	0.00143	0.00153	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—HTR2A—conduct disorder	0.0014	0.0015	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—DRD4—conduct disorder	0.00137	0.00147	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—DRD4—conduct disorder	0.00136	0.00147	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—DRD4—conduct disorder	0.00135	0.00145	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—HTR2A—conduct disorder	0.00132	0.00142	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—HTR2A—conduct disorder	0.00127	0.00136	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—DRD4—conduct disorder	0.0012	0.00129	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—WASF1—conduct disorder	0.00116	0.00124	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—WASF1—conduct disorder	0.00115	0.00124	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—DRD4—conduct disorder	0.00115	0.00123	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—WASF1—conduct disorder	0.00114	0.00123	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—CGA—conduct disorder	0.00112	0.0012	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CGA—conduct disorder	0.00103	0.00111	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CGA—conduct disorder	0.00102	0.0011	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—HTR2A—conduct disorder	0.000984	0.00106	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—HTR2A—conduct disorder	0.000981	0.00105	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—HTR2A—conduct disorder	0.000971	0.00104	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—HTR2A—conduct disorder	0.000893	0.00096	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—HTR2A—conduct disorder	0.00089	0.000957	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—HTR2A—conduct disorder	0.000882	0.000948	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—DRD4—conduct disorder	0.000809	0.000869	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—DRD4—conduct disorder	0.000806	0.000866	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—DRD4—conduct disorder	0.000798	0.000858	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—HTR2A—conduct disorder	0.000783	0.000841	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—COMT—conduct disorder	0.000777	0.000835	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—MAOA—conduct disorder	0.000772	0.000829	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—HTR2A—conduct disorder	0.000749	0.000805	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CGA—conduct disorder	0.000673	0.000723	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—HTR2A—conduct disorder	0.000528	0.000567	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—HTR2A—conduct disorder	0.000526	0.000565	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—HTR2A—conduct disorder	0.000521	0.00056	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—COMT—conduct disorder	0.000505	0.000543	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—MAOA—conduct disorder	0.000502	0.000539	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000486	0.000523	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—COMT—conduct disorder	0.000465	0.000499	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—MAOA—conduct disorder	0.000461	0.000496	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—COMT—conduct disorder	0.000461	0.000495	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—MAOA—conduct disorder	0.000457	0.000492	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000444	0.000477	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—EP300—conduct disorder	0.000415	0.000446	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—EP300—conduct disorder	0.000397	0.000427	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—EP300—conduct disorder	0.000333	0.000358	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—COMT—conduct disorder	0.000304	0.000326	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—MAOA—conduct disorder	0.000302	0.000324	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—EP300—conduct disorder	0.00028	0.0003	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—EP300—conduct disorder	0.000279	0.000299	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—EP300—conduct disorder	0.000276	0.000297	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—EP300—conduct disorder	0.000217	0.000233	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—EP300—conduct disorder	0.000199	0.000214	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—EP300—conduct disorder	0.000198	0.000212	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—EP300—conduct disorder	0.00013	0.00014	CbGpPWpGaD
